Latest News and Press Releases

- Dosing patients in both MAGE-A10 pilot studies in third cohort with range of one to six billion cells - - NY-ESO program transitioned to GSK allows clinical focus on wholly owned assets - -...

PHILADELPHIA and OXFORD, United Kingdom, July 26, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for...

LONDON and OXFORD, United Kingdom, July 24, 2018 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc and Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced...

PHILADELPHIA and OXFORD, United Kingdom, July 18, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of...

PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the...

- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts -  - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OXFORD,...

- No evidence of off-target toxicity at 100 million cells for second wholly owned asset -              - Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study...

PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the...

PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing...

- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO -  - Guidance confirmed, funded...